TLX

Telix Pharmaceuticals Ltd TLX

NasdaqMid CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,402 of 2,925

Why it scores 32Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$803.79M

Quarter to Dec 31

Net income

$-7.13M

Quarter to Dec 31

Free cash flow

$-42.98M

Quarter to Dec 31

Operating margin

3.7%

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$36.61M total
FMR LLC
$6.47M-0.6%
LAZARD ASSET MANAGEMENT LLC
$3.28M-2.0%
PORTLAND INVESTMENT COUNSEL INC.
$3.07M0.0%
Private Advisor Group, LLC
$2.27M+13.1%
MARSHALL WACE, LLP
$2.18MNew
MORGAN STANLEY
$1.91M+42.5%
Integrated Wealth Concepts LLC
$1.90M0.0%
Hennion & Walsh Asset Management, Inc.
$1.73MNew
UBS Group AG
$1.55M+317.0%
BLAIR WILLIAM & CO/IL
$1.42MNew
Raiffeisen Bank International AG
$1.30M-11.5%
Quadrature Capital Ltd
$1.18MNew
JPMORGAN CHASE & CO
$876.2K+35.2%
XY Capital Ltd
$822.0K+468.0%
XTX Topco Ltd
$793.0K+164.5%
Vanguard Personalized Indexing Management, LLC
$680.1K+77.4%
NLB Skladi, upravljanje premozenja, d.o.o.
$668.7KNew
Mariner, LLC
$427.6K-14.6%
Capricorn Fund Managers Ltd
$416.2KNew
GTS SECURITIES LLC
$409.7KNew
JANE STREET GROUP, LLC
$385.0KNew
IHT Wealth Management, LLC
$372.4K+29.0%
SummitTX Capital, L.P.
$364.6KNew
HRT FINANCIAL LP
$295.0KNew
Portolan Capital Management, LLC
$293.1K-95.3%
See all 62 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Operating Margin

FY 2025
EDGAR

ROIC

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

TLX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Telix Pharmaceuticals Ltd's annual filings on SEC EDGAR.

Telix Pharmaceuticals Ltd reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$803.8M$-7.1M3.7%
FY 2024$516.6M$33.7M10.7%
FY 2023$333.0M$4.2M3.3%
Source: TLX filings on SEC EDGAR →

Companies similar to TLX

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

TLX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Telix Pharmaceuticals Ltd (TLX): stock profile, AI score and financials

Telix Pharmaceuticals Ltd (TLX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TLX at 32.4/100 on a composite quality score built from its SEC filings, placing it at rank #2,402 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (FY 2025), Telix Pharmaceuticals Ltd reports quarterly revenue of $803.8M, net income of $-7.1M, an operating margin of 3.7%. Top institutional holders of TLX by reported 13-F value include FMR, LAZARD ASSET MANAGEMENT, PORTLAND INVESTMENT COUNSEL, based on the most recent SEC filings. TLX trades on the Nasdaq exchange and files with the SEC under CIK 2007191. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Telix Pharmaceuticals Ltd directly from SEC EDGAR.

SEC EDGAR: CIK 2007191 →